+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions



Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions



Pediatric Nephrology 20(10): 1376-1381



Clinicians are often faced with therapeutic dilemmas and challenges while treating children with frequently relapsing steroid-dependent nephrotic syndrome (SDNS) and steroid-resistant nephrotic syndrome (SRNS). In the past, children with SDNS have been treated with long-term alternate day steroids cyclophosphamide, cyclosporine (CSA), chlorambucil, levamisole, and azathioprine. The essential aim of these therapies is to maintain remission while limiting exposure to steroids. These medications have variable efficacy and undesirable toxicity profiles. Recently, mycophenolate mofetil (MMF) has emerged as a new therapeutic option for the management of SDNS in a few uncontrolled clinical trials. Preliminary data are encouraging. MMF was found to be useful in maintaining remission and has a steroid-sparing effect. Clearly, more data are needed to further characterize the safety and efficacy of MMF, define adequate length of treatment, and optimize drug exposure and monitoring. The management of SRNS is primarily aimed at decreasing proteinuria and inducing remission, if possible. By doing so, one would aim to preserve renal function. CSA therapy is known to be useful in this regard but has undesirable side effects, the most concerning being nephrotoxicity. MMF in combination with steroids and angiotensin-converting enzyme-inhibitor drugs is known to have some efficacy in the management of SRNS. These preliminary data have prompted the National Institutes of Health to sponsor a multicentric controlled trial to compare the safety and efficacy of MMF with that of CSA in the treatment of steroid-resistant focal segmental glomerulosclerosis (FSGS). If MMF therapy is found to be efficacious, it would help obviate the need for CSA and its associated nephrotoxicity. Clearly, MMF has emerged as an important new therapeutic option for the treatment of childhood nephrotic syndrome and FSGS. Further data are required to assess those conditions most likely to respond.

(PDF emailed within 0-6 h: $19.90)

Accession: 012337562

Download citation: RISBibTeXText

PMID: 15977023

DOI: 10.1007/s00467-005-1964-z


Related references

Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome. Nephrology 21(1): 21-27, 2016

Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome. Annals of Saudi Medicine 25(5): 380-384, 2005

Mycophenolate mofetil treatment in steroid resistant/relapsing nephrotic syndrome of childhood. Journal of the American Society of Nephrology 10(PROGRAM AND ABSTR ISSUE): 111A, Sept, 1999

Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome. Nephrology, Dialysis, Transplantation 20(10): 2243-2247, 2005

Immunosuppressive therapy in children with steroid-resistant, frequently-relapsing, and steroid-dependent idiopathic nephrotic syndrome: a single center experience. Electronic Physician 8(2): 2039-2047, 2016

Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrology, Dialysis, Transplantation 27(5): 1970-1978, 2012

Mycophenolate Sodium for Children with Frequently Relapsing or Steroid Dependent Nephrotic Syndrome. Indian Pediatrics 54(10): 885-886, 2017

Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome. Journal of Nephrology 24(2): 203-207, 2011

Renal biopsy bx in frequently relapsing steroid dependent steroid resistant nephrotic syndrome frns sdns srns in children two north american surveys. Journal of the American Society of Nephrology 3(3): 319, 1992

Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatric Nephrology 18(8): 833-837, 2003

Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome. Clinical Kidney Journal 10(5): 632-638, 2017

The Value of Monitoring the Serum Concentration of Mycophenolate Mofetil in Children with Steroid-Dependent/Frequent Relapsing Nephrotic Syndrome. Nephron 132(4): 327-334, 2016

Mycophenolate mofetil in treatment of childhood steroid-dependent nephrotic syndrome. La Tunisie Medicale 94(3): 221-225, 2016

Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatric Nephrology 20(7): 914-919, 2005

Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clinical Nephrology 72(4): 268-273, 2009